Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from Cyclosporin to Tacrolimus Sustained-release in Renal Transplant
NCT02706678Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Dec 2010
- Primary completion
- Aug 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus + Wuzhi capsule in kidney transplant rejection, sponsored by Astellas Pharma. Primary endpoint: Change from baseline in creatinine level at 24 weeks. Started Dec 2010; status: completed.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02706678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706678.